|
US6812327B1
(en)
*
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
|
US8212004B2
(en)
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
|
GB9828628D0
(en)
|
1998-12-23 |
1999-02-17 |
Glaxo Group Ltd |
Novel ligand
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
US20050100548A1
(en)
*
|
2001-07-24 |
2005-05-12 |
Biogen Idec Ma Inc. |
BAFF, inhibitors thereof and their use in the modulation of B-cell response
|
|
US6475987B1
(en)
|
1999-05-06 |
2002-11-05 |
National Jewish Medical And Research Center |
Tall-1 receptor homologues
|
|
EP1210425B2
(en)
|
1999-08-17 |
2015-06-17 |
Biogen MA Inc. |
Baff receptor (bcma), an immunoregulatory agent
|
|
UA74798C2
(uk)
*
|
1999-10-06 |
2006-02-15 |
Байоджен Айдек Ма Інк. |
Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
|
|
PT1255558E
(pt)
*
|
2000-02-16 |
2006-11-30 |
Genentech Inc |
Anticorpos anti-april e células hibridoma
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US7371388B1
(en)
|
2000-05-04 |
2008-05-13 |
Human Genome Sciences, Inc. |
Treatment of Sjogren's syndrome by administration of TR18 polypeptides
|
|
CA2408617A1
(en)
*
|
2000-05-12 |
2001-11-22 |
Amgen Inc. |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
|
EP2275449B1
(en)
*
|
2000-06-16 |
2016-09-28 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to BLyS
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
US20030091565A1
(en)
|
2000-08-18 |
2003-05-15 |
Beltzer James P. |
Binding polypeptides and methods based thereon
|
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
|
DE10049010A1
(de)
*
|
2000-10-04 |
2002-04-18 |
Boehringer Ingelheim Int |
Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
|
|
DK1436003T3
(da)
|
2001-05-24 |
2010-03-15 |
Zymogenetics Inc |
TACI-immunoglobulin-fusionsproteiner
|
|
KR20040019105A
(ko)
*
|
2001-08-03 |
2004-03-04 |
제넨테크, 인크. |
ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
|
|
US20080267965A1
(en)
*
|
2002-02-21 |
2008-10-30 |
Kalled Susan L |
Use of Bcma as an Immunoregulatory Agent
|
|
AU2003256836A1
(en)
*
|
2002-07-25 |
2004-02-16 |
Genentech, Inc. |
Taci antibodies and uses thereof
|
|
AU2004233164B2
(en)
*
|
2003-03-28 |
2009-10-08 |
Biogen Ma Inc. |
Truncated BAFF receptors
|
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
EP2272868B1
(en)
*
|
2003-06-05 |
2015-03-04 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
MXPA06004301A
(es)
|
2003-10-20 |
2006-06-05 |
Biogen Idec Inc |
Regimenes terapeuticos para antagonistas del factor de activacion de celulas b.
|
|
WO2005075511A1
(en)
*
|
2004-01-29 |
2005-08-18 |
Genentech, Inc. |
Variants of the extracellular domain of bcma and uses thereof
|
|
AU2005305182A1
(en)
*
|
2004-11-04 |
2006-05-18 |
Genentech, Inc. |
Polypeptides that bind BAFF and/or APRIL
|
|
CA2590461A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Laboratoires Serono S.A. |
Bcma polypeptides and uses thereof
|
|
CA2596276A1
(en)
*
|
2005-01-28 |
2006-08-03 |
Biogen Idec Ma Inc. |
Use of baff to treat th2-mediated conditions
|
|
AU2006278227B2
(en)
|
2005-08-09 |
2011-10-20 |
Ares Trading S.A. |
Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
|
|
ZA200801354B
(en)
|
2005-08-09 |
2009-08-26 |
Ares Trading Sa |
Methods for treating B-cell malignancies using TACI-lg fusion molecule
|
|
EA015860B1
(ru)
*
|
2005-10-13 |
2011-12-30 |
Хьюман Дженом Сайенсиз, Инк. |
Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
CA2629306A1
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
US8211649B2
(en)
|
2006-03-31 |
2012-07-03 |
Human Genome Sciences, Inc. |
Methods of diagnosing and prognosing hodgkin's lymphoma
|
|
EA015342B1
(ru)
|
2006-05-15 |
2011-06-30 |
Арес Трейдинг С.А. |
Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
|
|
JP5767109B2
(ja)
|
2008-07-17 |
2015-08-19 |
ノバルティス アーゲー |
治療抗体を用いる組成物及び方法
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
WO2010093993A2
(en)
*
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
HRP20161194T1
(hr)
|
2009-03-10 |
2016-11-04 |
Biogen Ma Inc. |
Anti-bcma protutijela
|
|
MX353186B
(es)
|
2009-09-03 |
2018-01-05 |
Genentech Inc |
Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
|
|
CN101781680B
(zh)
*
|
2009-10-19 |
2012-05-09 |
南通大学附属医院 |
测定对人baff-r基因启动子活性影响因素的方法
|
|
WO2011108008A2
(en)
*
|
2010-03-04 |
2011-09-09 |
Transgene Biotek Ltd. |
Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
|
|
CN103502472B
(zh)
|
2011-02-28 |
2017-06-06 |
弗·哈夫曼-拉罗切有限公司 |
生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
PH12013502421A1
(en)
*
|
2011-05-27 |
2014-01-06 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
JP2015506950A
(ja)
|
2012-01-31 |
2015-03-05 |
ジェネンテック， インコーポレイテッド |
抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
|
|
US10435474B2
(en)
|
2013-12-24 |
2019-10-08 |
Ossianix, Inc. |
Baff selective binding compounds and related methods
|
|
CN106459990B
(zh)
|
2014-02-07 |
2021-06-01 |
麦克马斯特大学 |
三功能t细胞抗原偶联物及其制备方法和用途
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
DK3226897T3
(da)
*
|
2014-12-05 |
2021-04-19 |
Memorial Sloan Kettering Cancer Center |
Antistoffer der rammer b-cellemodningsantigen og fremgangsmåder til anvendelse
|
|
SG10201900931XA
(en)
|
2014-12-05 |
2019-02-27 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
JP6921001B2
(ja)
|
2015-04-13 |
2021-08-18 |
ファイザー・インク |
Ｂ細胞成熟抗原を標的にするキメラ抗原受容体
|
|
ES3012402T3
(en)
|
2015-04-13 |
2025-04-09 |
Pfizer |
Therapeutic antibodies and their uses
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
CN108603200B
(zh)
|
2015-11-23 |
2022-08-19 |
诺华股份有限公司 |
优化的慢病毒转移载体及其用途
|
|
JP2019500394A
(ja)
|
2015-12-30 |
2019-01-10 |
ノバルティス アーゲー |
有効性が増強された免疫エフェクター細胞治療
|
|
IL311107A
(en)
|
2016-02-17 |
2024-04-01 |
Seagen Inc |
BCMA antibodies and their use for the treatment of cancer and immune disorders
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
EP4628094A2
(en)
*
|
2016-06-06 |
2025-10-08 |
City of Hope |
Baff-r antibodies and uses thereof
|
|
EP3471773A4
(en)
|
2016-06-21 |
2020-07-08 |
Teneobio, Inc. |
ANTIBODIES BINDING CD3
|
|
UA126384C2
(uk)
|
2016-09-14 |
2022-09-28 |
Тенеобіо, Інк. |
Антитіло, яке зв'язує cd3
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
IL267485B2
(en)
|
2016-12-21 |
2024-01-01 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies and uses thereof
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2018144535A1
(en)
|
2017-01-31 |
2018-08-09 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
US20200048359A1
(en)
|
2017-02-28 |
2020-02-13 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
MY201573A
(en)
|
2017-05-12 |
2024-03-02 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
EP3652209A2
(en)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonist antibodies that bind human cd137 and uses thereof
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
|
BR112020007576A2
(pt)
|
2017-10-18 |
2020-09-24 |
Novartis Ag |
composições e métodos para degradação de proteína seletiva
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
BR112020008638A2
(pt)
|
2017-11-01 |
2020-10-20 |
Juno Therapeutics Inc |
receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
|
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
AU2018359907A1
(en)
|
2017-11-06 |
2020-05-07 |
Fred Hutchinson Cancer Center |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
US20200360431A1
(en)
|
2017-11-15 |
2020-11-19 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
TW201925782A
(zh)
|
2017-11-30 |
2019-07-01 |
瑞士商諾華公司 |
靶向bcma之嵌合抗原受體及其用途
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
JP7542441B2
(ja)
|
2018-05-11 |
2024-08-30 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
癌を治療するための方法及び組成物
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
TWI848951B
(zh)
|
2018-06-01 |
2024-07-21 |
瑞士商諾華公司 |
針對ｂｃｍａ之結合分子及其用途
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
AU2019284911A1
(en)
|
2018-06-13 |
2020-12-17 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
MD3823665T2
(ro)
|
2018-07-19 |
2024-05-31 |
Regeneron Pharma |
Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
ES3042082T3
(en)
|
2018-08-31 |
2025-11-18 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
AU2019372331A1
(en)
|
2018-11-01 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
ES2982474T3
(es)
|
2019-02-15 |
2024-10-16 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
EP3927747A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
KR20210134339A
(ko)
|
2019-02-25 |
2021-11-09 |
노파르티스 아게 |
바이러스 전달을 위한 메조다공성 실리카 입자 조성물
|
|
WO2020191316A1
(en)
|
2019-03-21 |
2020-09-24 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
|
CN113710707B
(zh)
|
2019-04-05 |
2024-05-31 |
特尼奥生物股份有限公司 |
结合于psma的重链抗体
|
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
BR112021023048A2
(pt)
|
2019-05-21 |
2022-04-19 |
Novartis Ag |
Moléculas de ligação a cd19 e usos das mesmas
|
|
CN119564852A
(zh)
|
2019-06-14 |
2025-03-07 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
US20220257796A1
(en)
|
2019-07-02 |
2022-08-18 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
BR112022016633A2
(pt)
|
2020-02-27 |
2022-12-13 |
Novartis Ag |
Métodos para produzir células que expressam receptor de antígeno quimérico
|
|
US20230256017A1
(en)
|
2020-02-27 |
2023-08-17 |
Jennifer Brogdon |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN115715220A
(zh)
|
2020-04-29 |
2023-02-24 |
特尼奥生物股份有限公司 |
具有经修饰重链恒定区的多特异性重链抗体
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
MX2022015852A
(es)
|
2020-06-23 |
2023-01-24 |
Novartis Ag |
Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN116406371A
(zh)
*
|
2020-08-12 |
2023-07-07 |
斯坦福大学托管董事会 |
sBCMA变体及其Fc融合蛋白
|
|
US20230302155A1
(en)
|
2020-08-21 |
2023-09-28 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
|
CN118056008A
(zh)
|
2021-04-27 |
2024-05-17 |
诺华股份有限公司 |
病毒载体生产系统
|
|
KR20240037892A
(ko)
|
2021-06-01 |
2024-03-22 |
트리움비라 이뮤놀로직스 유에스에이, 인크. |
클라우딘 18.2 t 세포-항원 커플러 및 이의 용도
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
JP2024529128A
(ja)
|
2021-08-11 |
2024-08-01 |
アクソ バイオファーマシューティカル， インコーポレイテッド |
ｓＢＣＭＡバリアント及びそのＦＣ融合タンパク質を使用するＩｇＡ、ＩｇＭ、及び／又はＩｇＧの産生を低減する方法
|
|
WO2023021477A1
(en)
|
2021-08-20 |
2023-02-23 |
Novartis Ag |
Methods of making chimeric antigen receptor–expressing cells
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024197157A1
(en)
|
2023-03-21 |
2024-09-26 |
Biograph 55, Inc. |
Cd19/cd38 multispecific antibodies
|
|
WO2024243441A1
(en)
|
2023-05-24 |
2024-11-28 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2025170844A1
(en)
*
|
2024-02-05 |
2025-08-14 |
Board Of Regents, The University Of Texas System |
Chimeric polypeptides and methods of use
|